|
|
 |
|
Viewing report
|
|
|
|
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Business Insights, May 2011, Pages: 81
The report provides an in-depth analysis of the respiratory franchise. It also highlights the key R&D trends that may influence treatment sales and includes a thorough analysis of the competitive dynamics of leading brands within each indication, enabling the reader to identify growth of the leading brands, key drug classes and leading players through 2016.
Features and benefits
- Quantify patient potential and assess treatment trends and sales patterns across the major respiratory indications in the seven major markets.
- Discover which indications have the greatest potential to provide growth and understand the growth drivers of the major drug classes.
- Analyse the respiratory franchises of top pharmaceutical companies across major indications, and evaluate the market share of these companies.
- Gain comprehensive understanding of how recent events are affecting the performance of major products and companies.
- Forecast sales of the leading products as well as key pipeline products in the respiratory market over the period 2010–16.
Highlights
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment.
Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical companies, with an estimated 300 compounds in various stages of development. The COPD and allergic rhinitis pipelines are of lesser strength, comprising around 140 products.
Among several once-daily LABA/LAMA combinations in development, Boehringer Ingelheim’s BI1744/Spiriva is at an advantage as this combination product uses the current gold standard COPD treatment Spiriva. Other promising Phase III compounds in development include: Novartis’s NVA237 (glycopyrrolate) and GSK’s 642444 (vilanterol trifenatate). Novart
Your key questions answered
- What will be the major growth indications and the accompanying growth drivers in the global respiratory market over the period to 2016?
- Which companies have the strongest respiratory portfolios and ?
- What are the promising compounds in clinical development for major respiratory indications, and what is their forecast commercial potential?
- What are the current trends within the major therapy areas such as asthma/COPD and allergic rhinitis across the seven major markets?
- What are the recent regulatory changes in the respiratory arena and what will be thier impact on the marketed products?
|
|
|
|
